Opsutan 10 mg (Macitentan)
Opsutan 10 mg contains macitentan, an oral endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1). Macitentan reduces pulmonary vascular resistance, improves exercise capacity and may delay disease progression when used as part of specialist-directed PAH therapy.
Opsutan must be prescribed and managed by clinicians experienced in PAH due to safety considerations including pregnancy risk and laboratory monitoring.
Product introduction
Macitentan is a dual endothelin receptor antagonist (blocks ETA and ETB receptors) with good tissue penetration and a long receptor occupancy profile, designed to provide sustained endothelin pathway inhibition. The recommended maintenance dose for most adults is 10 mg once daily. Initiation, combination with other PAH therapies, and monitoring should follow specialist guidance.
Uses of Opsutan 10 mg (Macitentan)
Specialist indications include:
- Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening
- Use as part of combination therapy with PDE-5 inhibitors, prostacyclin analogues or other agents in selected patients
Note: Selection of ERA and combination regimens depends on patient risk profile, comorbidities and local guidelines.
Benefits of Opsutan 10 mg
- Improves exercise tolerance: demonstrated improvements in walk distance and symptoms in PAH trials.
- May slow disease progression: reduces clinical worsening events when used appropriately.
- Oral once-daily dosing: convenient for long-term outpatient treatment under monitoring.
Recommended dosing
The usual adult dosing is 10 mg once daily, taken at the same time each day with or without food. No routine up-titration is needed for most patients—follow your specialist’s prescription. Dose adjustments may be necessary in severe hepatic impairment or with interacting drugs—refer to product labeling and specialist advice.
Side effects of Opsutan 10 mg (Macitentan)
Macitentan is generally well tolerated in clinical use, but monitoring is required for specific adverse effects.
Common side effects
- Headache
- Nasopharyngitis and upper respiratory symptoms
- Peripheral oedema
- Anemia (decrease in hemoglobin)
- Fatigue
Important risks: fetal toxicity (teratogenicity) — macitentan is contraindicated in pregnancy. Monitor haemoglobin and signs of anaemia; report worsening oedema or breathlessness promptly. Seek urgent care for signs of severe allergic reactions or unexplained severe symptoms.
How to use Opsutan 10 mg
- Take one tablet (10 mg) once daily, at the same time each day.
- May be taken with or without food; swallow whole with water.
- Do not stop therapy abruptly—discuss planned interruptions with your PAH specialist.
- Inform all healthcare providers and pharmacists that you are taking macitentan (important for peri-procedural planning and drug interactions).
How Opsutan works
Macitentan blocks endothelin-1 signalling at ETA and ETB receptors in the pulmonary vascular bed, reducing vasoconstriction and vascular remodelling. This lowers pulmonary vascular resistance and improves right-heart function over time in PAH patients.
Safety advice
| Pregnancy | Contraindicated — macitentan can cause serious birth defects. Women of reproductive potential must have a negative pregnancy test before starting, use reliable contraception during treatment and continue contraception for 1 month after stopping. Discuss pregnancy plans with your specialist. |
| Haemoglobin / anaemia | Monitor haemoglobin at baseline and periodically. Macitentan can reduce haemoglobin; dose interruption or discontinuation may be required for significant anaemia. |
| Liver function | Monitor LFTs at baseline and as clinically indicated—macitentan has a more favourable liver profile than some ERAs but hepatic monitoring is recommended in routine practice. |
| Drug interactions | Macitentan is metabolised via CYP pathways. Avoid or adjust dosing with strong CYP3A4 inhibitors (e.g., ketoconazole) which may increase macitentan exposure; strong inducers (e.g., rifampin) may reduce efficacy. Check all medicines, herbal supplements and over-the-counter products with your clinician. |
| Concomitant PAH therapies | Often used in combination with PDE-5 inhibitors or prostacyclin analogues—these combinations should be managed by PAH specialists due to interaction and additive effect considerations. |
What if you forget a dose?
- Take the missed dose as soon as you remember on the same day.
- If it is almost time for the next dose, skip the missed dose and resume the usual schedule.
- Do not double the dose to make up for a missed tablet.
All substitutes
Other endothelin receptor antagonists and PAH therapies (specialist selection):
- Bosentan (dual ERA)
- Ambrisentan (selective ETA antagonist)
- PDE-5 inhibitors (sildenafil, tadalafil), prostacyclin analogues, soluble guanylate cyclase stimulators
Quick tips
- Register with any local pregnancy-prevention programme if required by local regulations.
- Carry an alert card stating you are taking macitentan.
- Bring recent haemoglobin and LFT results to clinic visits.
- Report unusual bleeding, severe breathlessness, increasing oedema or symptoms of anaemia immediately.
Fact Box
| Generic name | Macitentan |
| Brand | Opsutan 10 mg |
| Drug class | Endothelin receptor antagonist (dual ETA/ETB) |
| Form | Oral tablet (10 mg) |
| Typical dosing | 10 mg once daily (adjust as specialist advises) |
| Prescription | Specialist prescription & monitoring required |
Patient concerns
Will Opsutan cure PAH? No. Macitentan is used to improve symptoms, exercise capacity and reduce clinical worsening — it is part of long-term disease management rather than a cure.
Why do I need haemoglobin checks? Macitentan can cause decreases in haemoglobin; monitoring detects anaemia early so dose changes or treatment adjustments can be made safely.
User feedback
Specialist-treated patients report improved exercise tolerance and symptom stability when macitentan is used as part of a comprehensive PAH regimen. Common patient concerns include the need for regular blood tests and strict pregnancy prevention measures.
FAQs
Can I become pregnant while taking Opsutan?
No — macitentan is contraindicated in pregnancy. Effective contraception is required during therapy and for 1 month after stopping. Seek specialist advice for family planning.
Are regular blood tests needed?
Yes — baseline blood tests (haemoglobin, LFTs) and periodic monitoring are recommended. Your specialist will advise the frequency based on clinical response and local guidance.
How should I store Opsutan?
Store at room temperature away from moisture and heat. Keep out of reach of children and do not use past the expiry date.
Related products
- Ambrisentan (selective ERA)
- Bosentan (dual ERA)
- Sildenafil, Tadalafil (PDE-5 inhibitors)
- Prostacyclin analogues (specialist use)
Want to share the information?
Share this article to help patients and caregivers understand macitentan therapy and safe use in PAH.
Disclaimer:
This article is for educational purposes only and does not replace specialist medical advice. Opsutan (macitentan) must be prescribed and monitored by clinicians experienced in PAH management. Follow local product labelling and guidance.
Marketer details
genericurerx — support@genericurerx.com — www.genericurerx.com
In case of any issues, contact us
For ordering or prescription verification use live chat or our contact page. For medical concerns contact your PAH specialist immediately.
Lab tests offered by us
- Baseline & periodic haemoglobin
- Liver function tests (LFTs)
- Routine PAH follow-up (6MWD, BNP, echocardiography) as clinically indicated
Additional offers
Prescription coordination, PAH counselling and specialist referral support available on request. Use code GLOBAL10 where eligible for first-order discounts.
Reviews
There are no reviews yet.